# Dossier: SOLARIS VACCINES, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $249,723.00

**Award Date:** 2024-06-13

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

SOLARIS VACCINES, INC. is a biotechnology company focused on developing cell-free synthesized protein vaccines against rapidly evolving and emerging infectious diseases, particularly those posing biodefense threats. Their core mission is to accelerate vaccine development and production timelines, enabling a faster response to public health emergencies and national security threats. They aim to solve the problem of slow and cumbersome traditional vaccine manufacturing processes by utilizing a cell-free system that allows for rapid design, testing, and scalable production of vaccines, independent of traditional cell-based culture methods. Their unique value proposition lies in their ability to rapidly prototype and manufacture vaccines tailored to specific viral strains and variants, potentially delivering vaccines in weeks rather than months or years.

**Technology Focus:**

* Cell-free protein synthesis (CFPS) platform: enables rapid and scalable production of vaccines using a cell-free system. They boast production timelines that are significantly faster than traditional cell-based methods, potentially enabling vaccine production within weeks.
* Rapid vaccine design and prototyping: Leveraging bioinformatics and computational modeling, they can quickly design and test vaccine candidates against emerging viral strains.

**Recent Developments & Traction:**

* October 11, 2023:\*\* Solaris Vaccines awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). (Source: Company Press Release)
* November 17, 2022:\*\* Solaris Vaccines secures patent for Rapid Protein Synthesis Platform Technology. (Source: United States Patent and Trademark Office)

**Leadership & Team:**

* Michael J. Doyle, CEO
* Yelena Rozenburg, CSO

**Competitive Landscape:**

* Ginkgo Bioworks: While a broader synthetic biology company, Ginkgo Bioworks also has capabilities in cell-free protein synthesis and vaccine development. SOLARIS VACCINES differentiates itself by focusing exclusively on rapidly deployable vaccines for emerging threats, offering a more targeted solution.
* Moderna: Although not directly comparable due to Moderna's focus on mRNA vaccines, they are a competitor in the broader vaccine space. SOLARIS VACCINES' key differentiator is its use of cell-free protein synthesis which it claims offers faster production times and potentially greater flexibility in targeting specific viral variants, especially useful against bioweapons.

**Sources:**

* [https://www.solarisvaccines.com/](https://www.solarisvaccines.com/)
* [https://www.linkedin.com/company/solaris-vaccines/](https://www.linkedin.com/company/solaris-vaccines/)
* [https://sbir.nih.gov/](https://sbir.nih.gov/)
* [https://uspto.report/patent/grant/11499096](https://uspto.report/patent/grant/11499096)